You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antineoplastic Agents, Immunological

Showing 1 - 25 of 8,221
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Urinary Bladder Tumors, Urologic Tumors, Urogenital Tumors Trial in Shanghai (tislelizumab and BCG)

Recruiting
  • Urinary Bladder Neoplasms
  • +5 more
  • tislelizumab and BCG
  • Shanghai, Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Jun 10, 2021

Breast Cancer, Gynecologic Cancer, HNSCC Trial in Boston (STX-478, Fulvestrant)

Recruiting
  • Breast Cancer
  • +3 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 13, 2023

Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])

Not yet recruiting
  • Neoplasms
  • +2 more
  • Nivolumab Injection [Opdivo]
  • (no location specified)
Jul 19, 2023

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma Trial in

Recruiting
  • Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
  • Columbus, Ohio
  • +9 more
Aug 1, 2022

Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

Recruiting
  • Neoplasms
  • +12 more
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023

NSCLC, Antineoplastic Agents Trial in Edmonton (Experimental intervention)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Antineoplastic Agents
  • Experimental intervention
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
May 23, 2022

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Hormone Receptor Positive Breast Carcinoma, Breast Tumors, Tumors, Breast Trial in Italy (Liquid biopsy and CT scan)

Recruiting
  • Hormone Receptor Positive Breast Carcinoma
  • +6 more
  • Liquid biopsy and CT scan
  • Bergame, Bergamo, Italy
  • +6 more
Apr 13, 2023

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

Recruiting
  • Leukemia
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +9 more
Sep 9, 2022

Solid Tumor, Adult Trial in Providence, Nashville (DF6215)

Not yet recruiting
  • Solid Tumor, Adult
  • Providence, Rhode Island
  • +1 more
Oct 25, 2023

Locally Advanced/Metastatic Solid Tumors Trial (PE0116&PE0105)

Not yet recruiting
  • Locally Advanced/Metastatic Solid Tumors
  • (no location specified)
Mar 24, 2023

Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

Active, not recruiting
  • Multiple Myeloma
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +8 more
May 24, 2022

Leukemia, Myeloid, Acute, MDS Trial in Worldwide (CC-95251, Azacitidine)

Recruiting
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes
  • Marina Del Rey, California
  • +35 more
Mar 11, 2022

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

CIPN and it's Impact on Quality of Life in Patients Receiving

Not yet recruiting
  • Chemotherapy-induced Peripheral Neuropathy
    • (no location specified)
    Apr 24, 2023

    Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

    Not yet recruiting
    • Metastatic Colorectal Adenocarcinoma
    • +2 more
    • BET Bromodomain Inhibitor ZEN-3694
    • +6 more
    • (no location specified)
    Oct 25, 2023

    Reporting of AdVerse Events Associated With AnTicAncerRapy

    Recruiting
    • Cancer
    • Antineoplastic and Immunomodulating Agents
    • Caen, Basse Normandie, France
      Alexandre Joachim
    Jan 4, 2021

    Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma Trial (Autologous Tumor Infiltrating Lymphocytes, Melphalan,

    Not yet recruiting
    • Metastatic Uveal Melanoma
    • Metastatic Cutaneous Melanoma
    • Autologous Tumor Infiltrating Lymphocytes
    • +2 more
    • (no location specified)
    Oct 14, 2022

    Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

    Recruiting
    • Lung Neoplasm Malignant
    • +18 more
    • Fairfax, Virginia
      New Experimental Therapeutics of Virginia (NEXT Oncology)
    Mar 29, 2022

    COVID-19 Infection, Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Seattle (Questionnaire Administration,

    Suspended
    • COVID-19 Infection
    • +2 more
    • Questionnaire Administration
    • Sotrovimab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 24, 2023

    Urothelial Carcinoma, Anlotinib, Urogenital Tumors Trial in Tianjin (Anlotinib, Cisplatin, Carboplatin)

    Not yet recruiting
    • Urothelial Carcinoma
    • +6 more
    • Tianjin, China
      Tianjin Medical Unversity Second Hospital
    Aug 30, 2021

    NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +14 more
    • Glendale, California
    • +12 more
    Feb 2, 2023

    Adult Solid Tumor Trial (HLX26, HLX10)

    Recruiting
    • Adult Solid Tumor
    • Xuzhou, Jiangsu, China
      Xuzhou Central Hospital
    Oct 17, 2022